FI3182975T3 - Rukaparibin suuren annosvahvuuden tabletteja - Google Patents

Rukaparibin suuren annosvahvuuden tabletteja

Info

Publication number
FI3182975T3
FI3182975T3 FIEP15833096.9T FI15833096T FI3182975T3 FI 3182975 T3 FI3182975 T3 FI 3182975T3 FI 15833096 T FI15833096 T FI 15833096T FI 3182975 T3 FI3182975 T3 FI 3182975T3
Authority
FI
Finland
Prior art keywords
tablet according
weight
active pharmaceutical
pharmaceutical ingredient
tablet
Prior art date
Application number
FIEP15833096.9T
Other languages
English (en)
Finnish (fi)
Inventor
Jeffrey Etter
Original Assignee
Pharma& Schweiz Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharma& Schweiz Gmbh filed Critical Pharma& Schweiz Gmbh
Application granted granted Critical
Publication of FI3182975T3 publication Critical patent/FI3182975T3/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
FIEP15833096.9T 2014-08-22 2015-08-17 Rukaparibin suuren annosvahvuuden tabletteja FI3182975T3 (fi)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462040849P 2014-08-22 2014-08-22
US201562101739P 2015-01-09 2015-01-09
PCT/US2015/045522 WO2016028689A1 (en) 2014-08-22 2015-08-17 High dosage strength tablets of rucaparib

Publications (1)

Publication Number Publication Date
FI3182975T3 true FI3182975T3 (fi) 2025-11-13

Family

ID=55347324

Family Applications (1)

Application Number Title Priority Date Filing Date
FIEP15833096.9T FI3182975T3 (fi) 2014-08-22 2015-08-17 Rukaparibin suuren annosvahvuuden tabletteja

Country Status (23)

Country Link
US (3) US9987285B2 (https=)
EP (1) EP3182975B1 (https=)
JP (3) JP6574477B2 (https=)
KR (2) KR102803917B1 (https=)
CN (2) CN106794185A (https=)
AU (2) AU2015305696B2 (https=)
BR (1) BR112017000865A2 (https=)
CA (1) CA2955495C (https=)
DK (1) DK3182975T3 (https=)
ES (1) ES3048688T3 (https=)
FI (1) FI3182975T3 (https=)
HR (1) HRP20251484T1 (https=)
IL (1) IL249946B (https=)
LT (1) LT3182975T (https=)
MX (1) MX367260B (https=)
NZ (1) NZ728392A (https=)
PL (1) PL3182975T3 (https=)
PT (1) PT3182975T (https=)
RS (1) RS67356B1 (https=)
RU (1) RU2705156C2 (https=)
SG (1) SG11201700265VA (https=)
SI (1) SI3182975T1 (https=)
WO (1) WO2016028689A1 (https=)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12168004B2 (en) 2014-02-05 2024-12-17 Merck Sharp & Dohme Llc Treatment of migraine
RU2019123406A (ru) 2014-02-05 2019-10-03 Мерк Шарп И Доум Корп. Технология приготовления таблеток для cgrp-активных соединений
AU2015305696B2 (en) 2014-08-22 2019-08-29 Pharma& Schweiz Gmbh High dosage strength tablets of rucaparib
CN106008530B (zh) * 2016-07-24 2018-06-26 石家庄久正生物科技有限公司 一种抗卵巢癌药物Rucaparib关键中间体的制备方法
CN108201534A (zh) * 2016-12-16 2018-06-26 苏州苏融生物医药有限公司 一种瑞卡帕布口服缓控释药物组合物及其用途
WO2018140377A1 (en) 2017-01-24 2018-08-02 Assia Chemical Industries Ltd. Solid state forms of rucaparib and of rucaparib salts
CN110944638A (zh) 2017-03-27 2020-03-31 特沙诺有限公司 尼拉帕尼组合物
TWI843707B (zh) * 2017-09-26 2024-06-01 美商提薩羅有限公司 尼拉帕尼（ｎｉｒａｐａｒｉｂ）調配物
WO2019130229A1 (en) 2017-12-28 2019-07-04 Mylan Laboratories Ltd Methods and intermediates for preparing rucaparib
KR20200121800A (ko) 2018-01-05 2020-10-26 싸이브렉사 1, 인크. 산성 또는 저산소성 질환에 걸린 조직에 관련된 질환의 치료를 위한 화합물, 조성물 및 방법
US12383545B1 (en) 2018-06-08 2025-08-12 Allergan Pharmaceuticals International Limited Treatment of migraine
CN109111454A (zh) * 2018-08-01 2019-01-01 宁波金未生物科技有限公司 一种瑞卡帕布s-樟脑磺酸盐
CN108853030B (zh) * 2018-09-26 2021-10-01 上海朝晖药业有限公司 一种治疗恶性肿瘤的药物制剂及其制备方法
CN111542527A (zh) 2018-12-06 2020-08-14 上海诚妙医药科技有限公司 芦卡帕利樟脑磺酸盐的新晶型和制备方法及其用途
US11555019B2 (en) 2019-07-10 2023-01-17 Cybrexa 3, Inc. Peptide conjugates of microtubule-targeting agents as therapeutics
MX2022000449A (es) 2019-07-10 2022-04-25 Cybrexa 2 Inc Conjugados peptídicos de citotoxinas como terapéuticos.
US20230234938A1 (en) 2020-04-28 2023-07-27 Rhizen Pharmaceuticals Ag Novel compounds useful as poly(adp-ribose) polymerase (parp) inhibitors
EP4182318B1 (en) 2020-07-14 2025-08-27 Assia Chemical Industries Ltd. Solid state forms of rucaparib salts
CN116390712A (zh) 2020-07-29 2023-07-04 阿勒根制药国际有限公司 治疗偏头痛
WO2022090938A1 (en) 2020-10-31 2022-05-05 Rhizen Pharmaceuticals Ag Phthalazinone derivatives useful as parp inhibitors
CA3206184A1 (en) 2020-12-22 2022-06-30 Allergan Pharmaceuticals International Limited Treatment of migraine
CA3214298A1 (en) 2021-04-08 2022-10-13 Swaroop Kumar Venkata Satya VAKKALANKA Inhibitors of poly(adp-ribose) polymerase
EP4408418A1 (en) 2021-09-27 2024-08-07 Allergan Pharmaceuticals International Limited Combination comprising atogepant for treating migraine
JP2024543323A (ja) * 2021-11-10 2024-11-21 クリチテック，インコーポレイテッド ルカパリブ粒子およびその使用
EP4463232A1 (en) 2022-01-11 2024-11-20 Assia Chemical Industries Ltd. Solid state forms of rucaparib tosylate

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6495541B1 (en) 1999-01-11 2002-12-17 Agouron Pharmaceuticals, Inc. Tricyclic inhibitors of poly(ADP-ribose) polymerases
CA2520997A1 (en) 2003-03-31 2004-10-14 Stacie Sara Canan-Koch Salts of tricyclic inhibitors of poly(adp-ribose) polymerases
US7531530B2 (en) 2003-07-25 2009-05-12 Cancer Research Technology Limited Therapeutic compounds
MX2007003314A (es) 2004-09-22 2007-08-06 Pfizer Combinaciones terapeuticas que comprenden inhibidor de poli(adp-ribosa)polimerasas.
ATE551345T1 (de) 2004-09-22 2012-04-15 Pfizer Polymorphe formen des phosphatsalzes von 8-fluor- 2-ä4-ä(methylamino)methylüphenylü-1,3,4,5- tetrahydro-6h-azepinoä5,4,3-cdüindol-6-on
PT1794163E (pt) 2004-09-22 2010-03-01 Pfizer Método para a preparação de inibidores de poli(adpribose)- polimerases
CA2720744A1 (en) * 2008-04-09 2009-10-15 Lek Pharmaceuticals D.D. Granulation of active pharmaceutical ingredients
EP4166558A1 (en) 2010-02-12 2023-04-19 Pfizer Inc. Salts and polymorphs of 8-fluoro-2-{4- [(methylamino)methyl]phenyl}-1 ,3,4,5-tetrahydro-6h-azepino[5,4,3- cd]indol-6-one
CN108478577A (zh) * 2012-04-05 2018-09-04 沃泰克斯药物股份有限公司 可用作atr激酶抑制剂的化合物及其组合疗法
AU2015305696B2 (en) 2014-08-22 2019-08-29 Pharma& Schweiz Gmbh High dosage strength tablets of rucaparib

Also Published As

Publication number Publication date
DK3182975T3 (da) 2025-10-20
IL249946B (en) 2020-05-31
SI3182975T1 (sl) 2025-12-31
RS67356B1 (sr) 2025-11-28
AU2015305696A1 (en) 2017-02-02
JP2017525712A (ja) 2017-09-07
JP7127101B2 (ja) 2022-08-29
US9987285B2 (en) 2018-06-05
US10130636B2 (en) 2018-11-20
AU2019272064B2 (en) 2021-11-18
CA2955495C (en) 2023-09-19
US20160051561A1 (en) 2016-02-25
AU2015305696B2 (en) 2019-08-29
KR20170043597A (ko) 2017-04-21
WO2016028689A1 (en) 2016-02-25
NZ728392A (en) 2023-06-30
MX367260B (es) 2019-08-12
RU2017109139A3 (https=) 2019-03-06
CN113209033A (zh) 2021-08-06
CN106794185A (zh) 2017-05-31
US20180200260A1 (en) 2018-07-19
KR102803917B1 (ko) 2025-05-07
BR112017000865A2 (pt) 2017-12-05
EP3182975A4 (en) 2018-04-18
PT3182975T (pt) 2025-10-28
LT3182975T (lt) 2025-11-25
RU2017109139A (ru) 2018-09-24
HRP20251484T1 (hr) 2026-01-02
PL3182975T3 (pl) 2026-02-23
ES3048688T3 (en) 2025-12-11
EP3182975A1 (en) 2017-06-28
AU2019272064A1 (en) 2019-12-19
JP2020002149A (ja) 2020-01-09
JP2021038242A (ja) 2021-03-11
JP6574477B2 (ja) 2019-09-11
EP3182975B1 (en) 2025-10-01
SG11201700265VA (en) 2017-02-27
US20190099430A1 (en) 2019-04-04
KR20230097211A (ko) 2023-06-30
CA2955495A1 (en) 2016-02-25
IL249946A0 (en) 2017-03-30
MX2017001540A (es) 2017-05-11
JP6797980B2 (ja) 2020-12-09
RU2705156C2 (ru) 2019-11-05

Similar Documents

Publication Publication Date Title
FI3182975T3 (fi) Rukaparibin suuren annosvahvuuden tabletteja
JP2017525712A5 (https=)
HRP20240231T1 (hr) Farmaceutske formulacije inhibitora brutonove tirozin kinaze
CO6440564A2 (es) Composiciones farmacéuticas de liberación inmediata que comprenden oxicodona y naloxona
FI3435996T3 (fi) Elafibranori käytettäväksi primaarisen biliaarisen kolangiitin hoidossa
UA116334C2 (uk) Тверді форми дозування бендамустину
SG190448A1 (en) Rapidly dispersing granules, orally disintegrating tablets and methods
HRP20250604T1 (hr) Formulacije tableta neratinib maleata
HRP20240564T1 (hr) Novi farmaceutski sastav
MX2020002841A (es) Formulacion de valbenazina de alta dosis y composiciones, metodos y kits relacionados con la misma.
RU2011152105A (ru) Составы таблеток 3-цианохинолина и их применение
CL2013000677A1 (es) Composicion farmaceutica en forma de tabletas que comprenden microgranulos gastrointestinales que contienen 100 a 800 mg de rifaximina, hasta 30% p/p de excipientes extragranulares y un recubrimiento formador de pelicula; y uso para tratar una enfermedad infecciosa y/o inflamatoria del intestino, tal como la enfermedad de crohn.
AR074739A1 (es) Comprimidos de capecitabina de disgregacion rapida
AR100977A1 (es) Formulación compuesta para la administración oral que comprende ezetimiba y rosuvastatina, y un proceso para su preparación
JP2018527305A5 (https=)
RU2016117186A (ru) Комбинированная композиция, содержащая тадалафил и амлодипин
RU2016150178A (ru) Твёрдая дисперсия аллисартана изопроксила и фармацевтическая композиция
FI3509595T3 (fi) Hydroksipyridonaattiaktinidi-/lantanididekorporaatioaineiden formulaatioita
HK1214519A1 (zh) 雙用途硫酸鹽口服藥物組合物片劑及其使用方法
MX2014011033A (es) Composiciones farmaceuticas orales estables de liberacion inmediata que contienen prasugrel.
AR080256A1 (es) Formulaciones farmaceuticas solidas de ramipril y besilato de amlodipino y su preparacion
JP2015120758A5 (https=)
JP2017520619A5 (https=)
PH12016500120A1 (en) Anti-tuberculosis stable pharmaceutical composition in a form of a coated tablet comprising granules of isoniazid and granules of rifapentine and its process of preparation
MX391191B (es) Composiciones de liberación extendida de onapristona y métodos.